节点文献

ACNU与Vm-26合用治疗脑瘤的实验研究

Combination of Nimustine with Teniposide in Treatment for Patients with Brain Tumor

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 马胜林耿宝琴雍定国庄贤韩

【Author】 MA Sheng lin1*,GENG Bao qin2,YONG Ding guo2,ZHUANG Xian han21.Zhejiang Cancer Hospital, Hangzhou 310022, P.R.China2.Medical Academy of Zhejiang University, Hangzhou 310031, P.R.China

【机构】 浙江省肿瘤医院浙江大学医学院浙江大学医学院 浙江杭州310022浙江杭州310031浙江杭州310031

【摘要】 目的:观察尼莫司汀(nimustineACNU)与威猛(teniposideVm26)合用对脑瘤的增效作用。方法:体外采用MTT法比较ACNU、Vm26单用与两者合用对人脑胶质母细胞瘤株生长的抑制作用,动物实验以小鼠移植性脑瘤(G422)的皮下接种型及脑内接种型为材料,分别观察ACNU和Vm26单用与合用对两个动物模型的抑制作用,皮下接种型比较瘤块大小,脑内接种型则以生存时间为标准。结果:体内试验,脑瘤皮下接种型中单用ACNU、Vm26的抑瘤率分别为56.5%及82.8%,两者合用后达99.1%,且该组12只动物中有9只不出现肿瘤,脑瘤脑内接种型的结果为ACNU、Vm26单用生存率延长分别为7.7%及6.7%,而合用组为35.4%。体外试验显示Vm260.01或1μg/μl分别与ACNU1、4及8μg/μl合用有明显协同作用,同样ACNU0.5、2μg/μl分别与Vm26(0.01、0.1或0.25μg/μl)合用亦增效。以IC50为指标,ACNU2或6μg/μl与Vm26合用增强倍数分别为2及12倍。结论:体内外抗脑瘤试验的结果均显示ACNU与Vm26合用较两药单用时有显著增效作用。

【Abstract】 Objective: To investigate the combination effect of nimustine and teniposide in treament for the patients with brain tumor. Methods: The inhibition effect of single nimustine or single teniposide was compared with combined regimen in treatment of human glioma cell line by MTT (methyl thiazolyl tetrazolium)method in vitro. On the transplanting G422 mice model, single nimustine, single teniposide,and combined regimen inhibit the subcutis transplanted tumor (s.c group)and the intrabrain transplanted tumor model (intrabrain group) were tested, respectively, the former investigate it′s tumor sides,and the survival time at the later group. Results: In vivo the tumor inhibition rate of nimustine, teniposide alone in the s.c group were 56.5% and 82.8%, while the combined group it was 99.1%, furthermore, the tumor didnt grow in 9 of 12 mice at this group; In the intrabrain group,the survival prolonged rate of nimustine and teniposide singely were 7.7% and 6.7%;the combined group was 35.4%. In vitro trial, it showed synergetic effect by combined Vm 26 0.001 μg/μl, 1 μg/μl with nimustine 1 μg/μl,4 μg/μl,and 8 μg/μl, respectively. It was also obtained the same result by combined nimustine (0.5 μg/μl, 2 μg/μl) with teniposide (0.01 μg/μl, 0.1 μg/μl, 0.25 μg/μl), respectively. According IC50,nimustine 2 μg/μl or 6 μg/μl combined with teniposide,the increased multiple was 2 and 12 fold. Conclusion: Both in vivo and in vitro study showed that nimustine combined with teniposide can increase the treatment effect for human brain tumor significantly, compared with the two drugs used singly.

【关键词】 尼莫司汀威猛脑肿瘤
【Key words】 NimustineTeniposideBrain tumor
  • 【文献出处】 癌症 ,Chinese Journal of Cancer , 编辑部邮箱 ,2001年08期
  • 【分类号】R739.4
  • 【被引频次】14
  • 【下载频次】96
节点文献中: 

本文链接的文献网络图示:

本文的引文网络